| Cubicin (daptomycin) / Merck (MSD) |
NCT00093067: Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus |
|
|
| Completed | 3 | | NA | daptomycin | Cubist Pharmaceuticals LLC | Bacterial Endocarditis, Bacteremia | 11/04 | 02/05 | | |
NCT00770341: A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) |
|
|
| Completed | 3 | 122 | NA | Daptomycin 4 mg/kg, MK3009, Comparator: vancomycin, Daptomycin 6 mg/kg | Merck Sharp & Dohme LLC | Staphylococcal Infection | 02/10 | 02/10 | | |
DAPTOREA, NCT02142075: Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure |
|
|
| Completed | 3 | | Europe | Daptomycin | Poitiers University Hospital | Renal Failure, Critical Care, Gram Positive Bacteria | 09/15 | | | |
